Loading patent…
AssigneeWave Life Sciences Ltd.
InventorsChandra Vargeese, Meena, Nenad Svrzikapa, Susovan Mohapatra, Christopher J. Francis, Gregory L. Verdine, Anna Sokolovska
Estimating the term…
Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
An oligonucleotide having the structure of:
An oligonucleotide, wherein the oligonucleotide is a sodium salt of:
A chirally controlled composition of an oligonucleotide having the structure of:
A pharmaceutical composition, comprising a therapeutically efficient amount of an oligonucleotide and at least on pharmaceutical acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers, wherein the oligonucleotide has the structure of:
Dependencies are inferred from the claim text.